ES2012997A6 - Un procedimiento para la obtencion de una linea de celulas hibridas que producen un anticuerpo monoclonal. - Google Patents

Un procedimiento para la obtencion de una linea de celulas hibridas que producen un anticuerpo monoclonal.

Info

Publication number
ES2012997A6
ES2012997A6 ES8900430A ES8900430A ES2012997A6 ES 2012997 A6 ES2012997 A6 ES 2012997A6 ES 8900430 A ES8900430 A ES 8900430A ES 8900430 A ES8900430 A ES 8900430A ES 2012997 A6 ES2012997 A6 ES 2012997A6
Authority
ES
Spain
Prior art keywords
monoclonal antibody
carcinoma cells
antibody specific
surface antigen
human carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES8900430A
Other languages
English (en)
Inventor
Roberto L Ceriani
Jerry A Peterson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Muir Cancer & Aging Inst John
Original Assignee
Muir Cancer & Aging Inst John
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Muir Cancer & Aging Inst John filed Critical Muir Cancer & Aging Inst John
Publication of ES2012997A6 publication Critical patent/ES2012997A6/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

UN PROCEDIMIENTO PARA LA OBTENCION DE UNA LINEA DE CELULAS HIBRIDAS QUE PRODUCEN UN ANTICUERPO MONOCLONAL. SE DESCRIBE UN PROCEDIMIENTO DE OBTENCION DE UNA LINEA DE CELULAS HIBRIDAS QUE PRODUCE UN ANTICUERPO MONOCLONAL ESPECIFICO DE UN DETERMINANTE ANTIGENICO UNICO DE LA SUPERFICIE DE LAS CELULAS DE CARCINOMA DE MAMA HUMANO PERO QUE NO SE UNE AL TEJIDO DE MAMA HUMANO NORMAL. EL ANTIGENO SE HA CARACTERIZADO COMO UN COMPLEJO GLICOPROTEICO DEL TIPO MUCINICO DE ELEVADO PESO MOLECULAR, SUPERIOR A 400.000 DALTONES. ADEMAS, EL ANTICUERPO MONOCLONAL PRODUCIDO POR LA LINEA DE CELULAS HIBRIDAS PUEDE SER UTILIZADO EN EL DIAGNOSTICO GRAFICO Y EN EL TRATAMIENTO TERAPEUTICO DEL CANCER DE MAMA EN SERES HUMANOS.
ES8900430A 1988-02-08 1989-02-07 Un procedimiento para la obtencion de una linea de celulas hibridas que producen un anticuerpo monoclonal. Expired - Fee Related ES2012997A6 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15307288A 1988-02-08 1988-02-08
US27199488A 1988-11-16 1988-11-16

Publications (1)

Publication Number Publication Date
ES2012997A6 true ES2012997A6 (es) 1990-04-16

Family

ID=26850130

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8900430A Expired - Fee Related ES2012997A6 (es) 1988-02-08 1989-02-07 Un procedimiento para la obtencion de una linea de celulas hibridas que producen un anticuerpo monoclonal.

Country Status (6)

Country Link
EP (1) EP0401247A4 (es)
JP (1) JPH03503120A (es)
CN (1) CN1036793A (es)
AU (1) AU3049189A (es)
ES (1) ES2012997A6 (es)
WO (1) WO1989007268A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU625856B2 (en) * 1987-07-15 1992-07-16 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Second generation monoclonal antibodies having binding specificity to tag-72 and human carcinomas and methods for employing the same
US5075219A (en) * 1989-04-05 1991-12-24 John Muir Cancer & Aging Institute Monoclonal antibody which recognizes a specific glycoprotein of a human milk-fat globule membrane mucin antigen and said mucin antigen
GB9019553D0 (en) * 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
FR2693233B1 (fr) * 1992-07-02 1994-08-19 Inst Francais Du Petrole Dispositif de contrôle de l'injection pneumatique d'un mélange carbure dans un moteur à combustion interne à deux temps et utilisation associée.
GB2273099A (en) * 1992-11-10 1994-06-08 Asta Medica Ag Glycoprotein encoded by a human endogenous retrovirus K envelope gene
CA2154266A1 (en) * 1993-02-05 1994-08-18 John F. Codington Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US6274143B1 (en) 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
WO2012036094A1 (ja) * 2010-09-17 2012-03-22 独立行政法人産業技術総合研究所 肺癌鑑別マーカー

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522918A (en) * 1981-12-15 1985-06-11 Jeffery Schlom Process for producing monoclonal antibodies reactive with human breast cancer
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies

Also Published As

Publication number Publication date
JPH03503120A (ja) 1991-07-18
WO1989007268A1 (en) 1989-08-10
EP0401247A1 (en) 1990-12-12
CN1036793A (zh) 1989-11-01
EP0401247A4 (en) 1991-01-23
AU3049189A (en) 1989-08-25

Similar Documents

Publication Publication Date Title
NO913211L (no) Nytt monoklonalt antistoff mot nytt antigen knyttet til menneske-tumorer.
EP0260610A3 (en) Monoclonal antibodies against human tumour necrotic factor (tnf), and their use
PT86180A (en) Hybridonas producing monoclonal antibodies to new mucin epitopes
ES8705975A1 (es) Un metodo de deteccion o localizacion de celulas de carcinoma humano.
EP0161941A3 (en) Monoclonal antibody useful in the diagnosis of human stomach or breast cancer
NZ210867A (en) Tumour-specific monoclonal antibodies, production thereof and use
GB2186885B (en) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas
CA2192079A1 (en) Human Monoclonal Antibodies Specific to Cell Cycle Independent Glioma Surface Antigen
ES2012997A6 (es) Un procedimiento para la obtencion de una linea de celulas hibridas que producen un anticuerpo monoclonal.
GB2182949A (en) Monoclonal antibodies and antigens for human non-small cell lung carcinomas
CA2044421A1 (en) Squamous cell carcinoma-like immunoreactive antigen from human female urine
ATE71225T1 (de) Verwendung eines spezifischen tumorassoziierten antigens, sialosyllactotetraose, in diagnoseoder therapieverfahren bezueglich krebskrankheiten.
IE880976L (en) Human tumour-associated antigen
ZA879403B (en) Primary biliary cirrhosis autoantigen
EP0254593A3 (en) Preparation and uses of interferon-gamma
ATE130764T1 (de) Anti-idiotyp antikörper induktion eines antitumorenresponses.
ZA884777B (en) Antigen recognized by mca 16 88
EP0259807A3 (en) Complement-dependent cytolytic anti-trichomonas vaginalis monoclonal antibody and use thereof in therapy and in diagnosis
WO1991017187A3 (en) A 35kd tumor associated protein antigen: uses and methods of detection
ES2059539T3 (es) Metodo para la prevencion de la enfermedad del injerto frente al huesped.
GR3007245T3 (es)
NO914094L (no) Nytt monoklonalt antistoff mot nytt antigen forbundet medhumantumorer
ZA831050B (en) Antibodies and antigens useful in the diagnosis and treatment of cancer
IE861358L (en) Process for the in vitro immunization of human splenocytes¹against tumor associated antigens

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19991209